FDA Tentatively Approves First Generic Lenacapavir for HIV Prevention at $40 a Year

The US Food and Drug Administration granted tentative approval on 2 November 2026 to a generic version of lenacapavir manufactured by Dr. Reddy's Laboratories of India. The twice-yearly injectable is intended for HIV pre-exposure prophylaxis in 120 low- and middle-income countries covered by Gilead Sciences' voluntary licensing program. The expected annual cost is $40 per person.

Tentative approval allows the product to be purchased by the US government and supplied to those countries while the originator's patents remain in force in the United States. It does not authorize sale inside the US. Gilead's branded product, Yeztugo, carries a list price of $28,218 per year. The generic matches the current price of daily oral PrEP tablets but requires only two injections a year.

Lenacapavir works by inhibiting the HIV capsid protein. Two large clinical trials showed near-complete protection against acquisition of the virus in populations at high risk. More than 125,000 people in ten early-adopter African countries have already started the branded version. First generic supplies are expected to reach countries by the end of 2026, with broader availability in 2027.

The approval arrived 16 months after the FDA cleared Gilead's originator product in June 2025. Unitaid, the Clinton Health Access Initiative, and Wits RHI worked with Dr. Reddy's on the filing. Dr. Reddy's combined prevention and treatment indications in a single application under the 505(b)(2) pathway, which received priority review. The typical timeline for generic HIV drugs has historically run closer to a decade after originator approval.

Neil Buddy Shah, CEO of the Clinton Health Access Initiative, stated that the speed of this approval shows what becomes possible when access planning begins at the same time as originator development. The $40 price was set under a September 2025 agreement between Gilead, Unitaid, CHAI, and Wits RHI.

The product cannot be sold in high-income markets while patents hold. In the United States and other high-income countries, Yeztugo remains the only available version. Health Canada approved the branded product earlier in 2026, but public coverage negotiations continue. The FDA's tentative approval pathway has been used for years specifically to verify quality of HIV medicines destined for US-funded programs outside the country.

Practical differences for users are large. Daily oral PrEP requires consistent adherence. The injectable removes that daily step. Missed doses of oral PrEP reduce protection; the long-acting injection maintains levels for six months after each dose. Clinics that already deliver injectable contraception or other long-acting products can incorporate the schedule without new infrastructure for most sites.

Dr. Reddy's is one of the largest generic manufacturers globally. The company has previously supplied other antiretroviral products under voluntary licenses. Manufacturing at scale for the 120-country program will require additional capacity; the firm has indicated that initial shipments will begin next month.

The volume of people who could benefit remains substantial. UNAIDS estimates that roughly 1.3 million people acquire HIV each year, the large majority in the countries covered by the license. If the generic reaches the same coverage levels already achieved by oral PrEP in high-burden settings, the absolute number of infections averted would be measurable within the first two to three years of wide rollout.

Cost is only one constraint. Distribution, cold-chain or room-temperature stability of the injectable, training of providers, and demand generation still determine uptake. The $40 annual figure covers the drug itself; program costs for delivery sit on top of that number. Early adopter countries have already demonstrated that those program costs can be managed at scale for the branded product.

The approval does not change the patent status inside the United States or Europe. It does change the timeline and price for the majority of the world's new infections. The concrete fact is that a twice-yearly injectable now has a regulatory path and a published price of $40 per person per year for 120 countries, with first product expected before the end of 2026.